Covid vaccine developer CureVac shores up C-suite as it heads toward IPO

Local Covid-19 drugmaker CureVac has firmed up its executive team in advance of its much-anticipated IPO.   CureVac, which is based in Germany with U.S. headquarters in Boston, announced Tuesday that Dr. Franz-Werner Haas will become its permanent CEO. He stepped into the role on a temporary basis in March after a week in which CureVac went through two chief executives.  The company has also lured I gor Splawski over from the Novartis Institutes for Biomedical Research in Cambridge to serve as…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

The World Health Organization (WHO) has released a preliminary framework for the global allocation of COVID-19 vaccines when they become available. The plan is intended to guide policymakers at the global, regional, and national level in their allocation and prioritization decisions about vaccines. WHO’s “fair allocation mechanism” emphasizes equitable allocation of vaccines and lists groups of people that should have priority access. The plan proposes vaccine distribution in two phases. In the first phase, all countries would receive vaccine doses in proportion to their population size - initially enoug...
Source: Public Policy Reports - Category: Biology Authors: Source Type: news
Johnson&Johnson has signed a manufacturing deal for its coronavirus vaccine candidate with Grand River Aseptic Manufacturing Inc, the contract manufacturing organization said on Friday.Reuters Health Information
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Infectious Diseases News Source Type: news
The global death toll from COVID-19 could double to 2 million before a successful vaccine is widely used and could be even higher without concerted action to curb the pandemic, a WHO official said on Friday.Reuters Health Information
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Infectious Diseases News Source Type: news
Condition:   COVID-19 Interventions:   Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector);   Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo Sponsors:   CanSino Biologics Inc.;   Beijing Institute of Biotechnology;   Jiangsu Province Centers for Disease Control and Prevention Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Global initiative will supply 120m rapid antigen tests to low- and middle-income countriesCoronavirus – latest updatesSee all our coronavirus coverageTests for Covid-19 that show on-the-spot results in 15 to 30 minutes are about to be rolled out across the world, potentially saving many thousands of lives and slowing the pandemic in both poor and rich countries.In a triumph for a global initiative to get vital drugs and vaccines to fight the virus, 120m rapid antigen tests from two companies will be supplied to low- and middle-income countries for $5 ( £3.90) each or even less.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Coronavirus outbreak World news World Health Organization European commission Infectious diseases Medical research Source Type: news
Substance has had promising results in ferrets, with hopes it may reduce transmissionCoronavirus – latest updatesSee all our coronavirus coverageA nasal spray is under development that could nip a coronavirus infection in the bud, with promising results already seen in ferrets, researchers have revealed.With coronavirus infections surging around the world, the race is on to develop a vaccine. But researchers are also looking for other ways to tackle Covid-19.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Coronavirus outbreak Drugs Science UK news Infectious diseases Medical research Source Type: news
cbsoptanon.onScriptsReady(function(cmp){cmp.ot.targetingAllowed(function(a){if(a) AnvatoPlayer("p0").init({"mcp":"cbs","width":"100%","height":"100%","video":"4743798","autoplay":false,"titleVisible":false,"accessKey":"EZqvRyKE7qmqDflDPXIw6U7kKZEA0Vx7","accessControl":{"preview":false},"pInstance":"p0","plugins":{"heartbeat":{"account":"cbslocal-global-unified","publisherId":"cbslocal","jobId...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Boston News Health Syndicated CBSN Boston Flu Vaccine Source Type: news
Source: BMJ News - Category: General Medicine Source Type: research
Inovio Pharmaceutical Inc.'s stock price plunged more than 34% Monday morning after the Plymouth Meeting biotech company announced a delay in the planned late-stage testing of its Covid-19 vaccine candidate. Shares of the company were down $5.77 to $16.94 a share in premarket trading. Inovio (NASDAQ: INO) said Monday the Food and Drug Administration told the company it has additional questions about Inovio's planned phase II/III clinical trial of its experimental vaccine candidate INO-4800 The…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
The agency’s response to the worst public health crisis in a century has been marked by technical mistakes, botched messaging, false accusations and interference by Trump administration political appointees.
Source: Washington Post: To Your Health - Category: Consumer Health News Authors: Source Type: news
More News: COVID-19 | Germany Health | Health Management | Pharmaceuticals | Vaccines